Technical Analysis for VTYX - Ventyx Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.72 | -3.37% | -0.06 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | -3.37% | |
| Lower Bollinger Band Walk | Weakness | -3.37% | |
| Wide Bands | Range Expansion | -3.37% |
| Alert | Time |
|---|---|
| Down 3% | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Fell Below Previous Day's Low | about 20 hours ago |
| Down 2 % | about 20 hours ago |
| New 52 Week Low | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/04/2024
Ventyx Biosciences, Inc. Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Autoimmune Disease Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Autoimmune Disorders Cytokine Lupus Immune Mediated Diseases Psoriatic Arthritis Molecule Product Inflammasome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.48 |
| 52 Week Low | 1.72 |
| Average Volume | 1,218,600 |
| 200-Day Moving Average | 3.56 |
| 50-Day Moving Average | 2.20 |
| 20-Day Moving Average | 2.10 |
| 10-Day Moving Average | 1.98 |
| Average True Range | 0.13 |
| RSI (14) | 29.58 |
| ADX | 17.97 |
| +DI | 15.43 |
| -DI | 31.31 |
| Chandelier Exit (Long, 3 ATRs) | 2.11 |
| Chandelier Exit (Short, 3 ATRs) | 2.10 |
| Upper Bollinger Bands | 2.47 |
| Lower Bollinger Band | 1.73 |
| Percent B (%b) | -0.02 |
| BandWidth | 35.23 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.07 |
| MACD Histogram | -0.0516 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.87 | ||||
| Resistance 3 (R3) | 1.89 | 1.85 | 1.85 | ||
| Resistance 2 (R2) | 1.85 | 1.82 | 1.85 | 1.84 | |
| Resistance 1 (R1) | 1.79 | 1.79 | 1.77 | 1.77 | 1.83 |
| Pivot Point | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
| Support 1 (S1) | 1.69 | 1.72 | 1.67 | 1.67 | 1.61 |
| Support 2 (S2) | 1.65 | 1.69 | 1.65 | 1.60 | |
| Support 3 (S3) | 1.59 | 1.65 | 1.60 | ||
| Support 4 (S4) | 1.57 |
